EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?

Simone Karp, Karolin Trautmann-Grill, Paul Warncke, Dominik Zolnowski, Christoph Röllig, Marcel Pannach, Jessica Zinn, Frank Kroschinsky, Anke Morgner, Malte von Bonin, Annette Hänel, Regina Herbst und 4 weitere

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06262-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Simone Karp und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Klinikum Chemnitz gGmbH, Chemnitz, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma, Salvage Therapy, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For patients (pts) with relapsed or refractory multiple myeloma (RRMM) after previous autologous hematopoietic cell transplantation (AHCT), novel agents, cellular and immunotherapies are increasingly available. Options for second-line treatment mostly include triplet regimens based on proteasome inhibitors, immunomodulatory drugs and anti-CD38 monoclonal antibodies and since recently also CAR T cells. The importance of autologous salvage transplantation (retransplantation, Re-AHCT) has significantly decreased in recent years due to the availability of many new treatment options. Therefore, we performed a retrospective analysis of 171 pts cases with RRMM who received Re-AHCT between 2002 and 2021. With a median follow-up of 74.7 months, the 5-year rates of progression-free survival (PFS) and overall survival (OS) were 18% (median 20.6 months) and 57% (median 65.0 months), respectively, the 100-day mortality rate was 4%. Multivariate analysis identified R-ISS stage and duration of previous response (DoR) as independent prognostic factors for PFS and OS. While the revealed high-risk population (R-ISS stage II/III, DoR ≤ 24 months) was associated with a significantly worse PFS (HR 2.728) and OS (HR 3.129), the low-risk group (R-ISS I, DoR > 24 months) achieved a median PFS and OS of 45.0 months and 80.2 months, respectively. Therefore, Re-AHCT could remain an option in such prognostically favorable pts with RRMM even in the era of novel therapies especially when more potent treatment modalities are not available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaSalvage TherapyHematopoietic Stem Cell TransplantationHumansMiddle AgedMaleFemaleRetrospective StudiesAgedAdultTransplantation, AutologousFollow-Up StudiesSurvival RateRecurrence

Stichwörter der Autor:innen

Autologous hematopoetic cell transplantationMultiple myelomaRelapseRetransplantationSalvage autologous

Autor:innen und Institutionen

  • Department of Internal Medicine III, Klinikum Chemnitz gGmbH, Chemnitz, Germany.
  • Medical Campus Chemnitz, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
  • Department of Internal Medicine I, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
  • Department of Internal Medicine III, Klinikum Chemnitz gGmbH, Chemnitz, Germany. m.haenel@skc.de.
  • Medical Campus Chemnitz, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany. m.haenel@skc.de.

Förderung

  • Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden

Zitieren

APA

Karp, S., Trautmann-Grill, K., Warncke, P., Zolnowski, D., Röllig, C., Pannach, M., Zinn, J., Kroschinsky, F., Morgner, A., von Bonin, M., Hänel, A., Herbst, R., Fricke, S., Bornhäuser, M., Hänel, M., & Teipel, R. (2025). Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?. Annals of Hematology. https://doi.org/10.1007/s00277-025-06262-9

Vancouver

Karp S, Trautmann-Grill K, Warncke P, Zolnowski D, Röllig C, Pannach M, et al. Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?. Annals of Hematology. 2025. doi:10.1007/s00277-025-06262-9

BibTeX
@article{Karp2025,
  author = {Karp, Simone and Trautmann-Grill, Karolin and Warncke, Paul and Zolnowski, Dominik and Röllig, Christoph and Pannach, Marcel and Zinn, Jessica and Kroschinsky, Frank and Morgner, Anke and von Bonin, Malte and Hänel, Annette and Herbst, Regina and Fricke, Stephan and Bornhäuser, Martin and Hänel, Mathias and Teipel, Raphael},
  title = {Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06262-9}
}
Kostenlos starten →